We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use an interrupted time series to evaluate your digital health product.
Information for patients, public and health care professionals.
How to use a quasi-experimental study to evaluate your digital health product.
Get a preferential rate on goods you import to the UK from a Developing Countries Trading Scheme country.
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
Engage with the Ministry of Defence (MOD) on SKYNET Enduring Capability (SKEC), the next generation of solutions for future satellite communication programmes.
This ground-breaking programme of research by the IPO looks at the various strategic drivers for intellectual property and the impact this has on IP demand.
Using an ecological momentary assessment to evaluate your digital health product.
Helping public health practitioners conducting evaluations – developing a logic model to represent how your intervention works.
How to use a factorial randomised controlled trial to evaluate your digital health product.
How to make an origin declaration if you're using it as proof of origin for products using the Developing Countries Trading Scheme.
VDEC’s Discovery and surveillance capabilities provide unique services across a spectrum of molecular immunology platforms.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
This guidance explains the Developing Countries Trading Scheme (DCTS) and how businesses can use it to export products to the UK.
This guidance explains what rules of origin (RoOs) are and the changes under the Developing Countries Trading Scheme (DCTS).
How to market, trial and release GMOs.
Sets out special provisions for Crown development for dealing with security-sensitive information in planning applications.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
Lassa virus causes Lassa fever, an acute viral haemorrhagic fever (VHF).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).